A Phase 3 interventional study of ABT-450/r/ABT-267, ABT-333 and Ribavirin (RBV) in Chronic Hepatitis C Infection and Compensated Cirrhosis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-07-12.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing paritaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. paritaprevir · Hepatitis C, Chronic.
Among the 16 studies testing paritaprevir in Hepatitis C, Chronic, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 3rd registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 16 studies testing paritaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 10 · Phase 4 1
First in 2012; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 381 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 124 across the 16 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
83 studies in Hepatitis C, Chronic by AbbVie: none open now, none under way, none of them phase 3. Of 82 finished, 74 (90%) have results posted.
Among the 83 studies in Hepatitis C, Chronic by AbbVie, this one is the 13th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2012, is one of 40 in phase 3, and was the 8th registered.
AbbVie’s Hepatitis C, Chronic studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing paritaprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 83 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis.
During the treatment period of the study, participants received treatment with ABT-450/ritonavir/ABT-267 and ABT-333 coadministered with RBV for either 12 or 24 weeks. Upon completing the treatment period or premature discontinuation of the treatment period, participants entered a 48-week post-treatment period.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
This study's enrollment of 381 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Browse Hepatitis C, Chronic studies →AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
Compared within Hepatitis C, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin (RBV)
ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks
Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin (RBV)
Drug pages: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir
Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
Also known as: Viekira Pak; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; ABT-333 also known as dasabuvir
Capsule
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of study drug
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm
A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (\< LLOQ) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of study drug
Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation \[≥ LLOQ\] after HCV RNA \< LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA \[2 consecutive HCV RNA measurements \> 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline\] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks \[≥ 36 days\] of treatment).
Time frame: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Percentage of Participants With Virologic Relapse After Treatment
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.
Time frame: within 12 weeks after the last dose of study drug
| Milestone | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks |
|---|---|---|
| Started | 208 | 172 |
| Completed study drug | 204 | 163 |
| Completed | 196 | 165 |
| Not completed | 12 | 7 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Withdrew consent | 1 | 1 |
| Withdrew: Other (not specified) | 3 | 1 |
| Withdrew: Withdrew consent and personal issues | 1 | 0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
| Percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment | 91.8 | 96.5 |
A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (\< LLOQ) 12 weeks after the last dose of study drug.
| Percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm | 91.8 | 96.5 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation \[≥ LLOQ\] after HCV RNA \< LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA \[2 consecutive HCV RNA measurements \> 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline\] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks \[≥ 36 days\] of treatment).
| Percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks |
|---|---|---|
| Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period | 0.5 (0.0 to 1.4) | 1.7 (0.0 to 3.7) |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.
| Percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks |
|---|---|---|
| Percentage of Participants With Virologic Relapse After Treatment | 5.9 (2.7 to 9.2) | 0.6 (0.0 to 1.8) |
Collected over Adverse events were collected from the time of study drug administration until 30 days after the last dose, 16 weeks for the 12-week treatment group and 28 weeks for the 24-week treatment group.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | — | 13/208 (6.3%) | 175/208 (84.1%) |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | — | 7/172 (4.1%) | 146/172 (84.9%) |
| Event | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks |
|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 1/208 | 1/172 |
| HAEMATEMESISGastrointestinal disorders | 0/208 | 1/172 |
| MELAENAGastrointestinal disorders | 0/208 | 1/172 |
| OESOPHAGEAL VARICES HAEMORRHAGEGastrointestinal disorders | 0/208 | 1/172 |
| CELLULITISInfections and infestations | 0/208 | 1/172 |
| FALLInjury, poisoning and procedural complications | 0/208 | 1/172 |
| HEAD INJURYInjury, poisoning and procedural complications | 0/208 | 1/172 |
| BLOOD GLUCOSE INCREASEDInvestigations | 0/208 | 1/172 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/208 | 1/172 |
| HEPATOCELLULAR CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/208 | 1/172 |
| Event | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks |
|---|---|---|
| FATIGUEGeneral disorders | 68/208 | 80/172 |
| HEADACHENervous system disorders | 58/208 | 53/172 |
| NAUSEAGastrointestinal disorders | 36/208 | 35/172 |
| PRURITUSSkin and subcutaneous tissue disorders | 38/208 | 33/172 |
| INSOMNIAPsychiatric disorders | 32/208 | 31/172 |
| DIARRHOEAGastrointestinal disorders | 30/208 | 29/172 |
| RASHSkin and subcutaneous tissue disorders | 23/208 | 25/172 |
| ASTHENIAGeneral disorders | 29/208 | 22/172 |
| IRRITABILITYGeneral disorders | 15/208 | 21/172 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 12/208 | 21/172 |
All participants who received at least 1 dose of study drug.
| Age, Continuous(years) | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | Total |
|---|---|---|---|
| Mean | 57.1 ± 7.01 | 56.5 ± 7.87 | 56.8 ± 7.41 |
| Sex: Female, Male(Participants) | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | Total |
|---|---|---|---|
| Female | 62 | 51 | 113 |
| Male | 146 | 121 | 267 |
No study locations are listed for this record.
The record gives a start of Oct 2012, a primary completion of Jan 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir · Ribavirin
AbbVie (prior sponsor, Abbott) →